{"Importance": [0], "Malignant": [1], "primary": [2, 21, 62, 243, 275, 290], "brain": [3, 23, 46, 59, 81, 113, 267, 277, 292], "tumors": [4, 24, 47, 60, 82, 183, 278, 293], "cause": [5], "more": [6], "than": [7], "15": [8], "000": [9, 30, 284], "deaths": [10], "per": [11, 28, 282], "year": [12], "in": [13, 217, 226], "the": [14, 107, 145, 196, 218, 227, 312], "United": [15], "States.": [16], "The": [17, 272], "annual": [18], "incidence": [19, 273], "of": [20, 44, 72, 79, 121, 136, 147, 198, 242, 274, 289], "malignant": [22, 45, 58, 70, 80, 276, 291], "is": [25, 38, 106, 279, 306], "approximately": [26, 39, 280, 287], "7": [27, 281], "100": [29, 283], "individuals": [31], "and": [32, 50, 69, 75, 91, 100, 123, 131, 139, 201, 222, 257, 270, 286, 311], "increases": [33], "with": [34, 119, 143, 149, 155, 180, 184, 195, 254], "age.": [35], "Five-year": [36], "survival": [37, 152, 190], "36%.": [40], "Observations": [41], "Approximately": [42], "49%": [43, 288], "are": [48, 52, 294], "glioblastomas,": [49], "30%": [51], "diffusely": [53], "infiltrating": [54], "lower-grade": [55], "gliomas.": [56], "Other": [57], "include": [61, 83], "central": [63], "nervous": [64], "system": [65], "(CNS)": [66], "lymphoma": [67, 245], "(7%)": [68], "forms": [71], "ependymomas": [73], "(3%)": [74], "meningiomas": [76], "(2%).": [77], "Symptoms": [78], "headache": [84], "(50%),": [85], "seizures": [86], "(20%-50%),": [87], "neurocognitive": [88], "impairment": [89], "(30%-40%),": [90], "focal": [92], "neurologic": [93], "deficits": [94], "(10%-40%).": [95], "Magnetic": [96], "resonance": [97], "imaging": [98, 109], "before": [99], "after": [101], "a": [102, 134], "gadolinium-based": [103], "contrast": [104], "agent": [105, 315], "preferred": [108], "modality": [110], "for": [111, 304], "evaluating": [112], "tumors.": [114], "Diagnosis": [115], "requires": [116], "tumor": [117, 129], "biopsy": [118], "consideration": [120], "histopathological": [122], "molecular": [124], "characteristics.": [125], "Treatment": [126, 241], "varies": [127], "by": [128, 251, 309], "type": [130], "often": [132], "includes": [133, 246], "combination": [135, 146, 197], "surgery,": [137], "chemotherapy,": [138], "radiation.": [140, 268], "For": [141], "patients": [142, 179, 297], "glioblastoma,": [144], "temozolomide": [148], "radiotherapy": [150, 156, 192], "improved": [151], "when": [153], "compared": [154], "alone": [157], "(2-year": [158], "survival,": [159, 164], "27.2%": [160], "vs": [161, 166, 194, 205, 224], "10.9%;": [162], "5-year": [163], "9.8%": [165], "1.9%;": [167], "hazard": [168], "ratio": [169], "[HR],": [170], "0.6": [171], "[95%": [172, 211, 235], "CI,": [173, 212, 236], "0.5-0.7];": [174], "P": [175, 214, 238], "&amp;amp;lt;": [176], ".001).": [177], "In": [178], "anaplastic": [181], "oligodendroglial": [182], "1p/19q": [185], "codeletion,": [186], "probable": [187], "20-year": [188], "overall": [189], "following": [191], "without": [193], "procarbazine,": [199], "lomustine,": [200], "vincristine": [202], "was": [203], "13.6%": [204], "37.1%": [206], "(80": [207], "patients;": [208, 232], "HR,": [209, 233], "0.60": [210], "0.35-1.03];": [213], "=": [215, 239], ".06)": [216], "EORTC": [219], "26951": [220], "trial": [221, 230], "14.9%": [223], "37%": [225], "RTOG": [228], "9402": [229], "(125": [231], "0.61": [234], "0.40-0.94];": [237], ".02).": [240], "CNS": [244], "high-dose": [247], "methotrexate-containing": [248], "regimens,": [249, 264], "followed": [250, 308], "consolidation": [252], "therapy": [253, 303], "myeloablative": [255], "chemotherapy": [256, 263], "autologous": [258], "stem": [259], "cell": [260], "rescue,": [261], "nonmyeloablative": [262], "or": [265], "whole": [266], "Conclusions": [269], "Relevance": [271], "individuals,": [285], "glioblastomas.": [295], "Most": [296], "die": [298], "from": [299], "progressive": [300], "disease.": [301], "First-line": [302], "glioblastoma": [305], "surgery": [307], "radiation": [310], "alkylating": [313], "chemotherapeutic": [314], "temozolomide.": [316]}